NetworkNewsWire Editorial Coverage: A tsunami has started: Cannabidiol (CBD), a non-psychoactive compound found in the cannabis sativa plant, has shown tremendous promise for broad-ranging medical benefits, and consumers are taking notice. CBD products are derived from either industrial hemp or marijuana plants, and sales have soared as companies scramble to exploit the enormous opportunity. Total CBD sales exceeded $200 million in 2016, and conservative projections peg overall sales in excess of $2.1 billion by 2020, a 700% increase from 2016. The hemp-derived CBD market is projected to grow at an astounding compounded annual growth rate approaching 55% over the next five years, positioning it as the fastest growing sub-segment within the multi-billion-dollar legal cannabis and hemp market. Some of the most promising players in the space include PotNetwork Holding Inc. (POTN) (POTN Profile), given a four-fold price target by a an equity research firm, Terra Tech Corp (TRTC), INSYS Therapeutics Inc. (INSY), Cannabis Science Inc. (CBIS) and 22nd Century Group Inc. (XXII).
Thousands of scientific studies tout the benefits of medical CBD. Research continues to be encouraging for CBD’s anti-seizure properties, singularly effective in treating certain epilepsies. Its effect on epilepsy and lack of significant side effects makes CBDs an attractive treatment option for multiple neurological disorders such as neurodegeneration, neuronal injury, and psychiatric diseases. CBD significantly reduces inflammation, and is already used to treat chronic pain, multiple sclerosis, and fibromyalgia. CBD has also demonstrated promising therapeutic results treating multiple anxiety disorders, mood symptoms, rheumatoid arthritis, nausea and insomnia. But the list of benefits is only growing. It appears to ease inflammation in the pancreas in Type 1 diabetes; there’s evidence that it has potential to prevent Alzheimer’s disease symptoms; and CBD appears to suppress the growth of cancer cells and promote the death of these cells (http://nnw.fm/Gag71). In multiple studies, CBD has been well-tolerated in adults across a wide range of dosages. With so many direct applications, the prospects of combination pharmaceutical therapies and the promise of a myriad of new remedies, it is little wonder the CBD market is exploding, and companies are vying to capitalize on the immense opportunity.
Read the full article
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Mounting Evidence on Therapeutic Benefits of Cannabis Unleashes Tsunami
